High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer

These HDR-BT schedules achieved high levels of biochemical control of disease in patients with advanced prostate cancer with few severe complications seen throughout the first 3 years.